MYRBETRIQ™ (mirabegron)
This slideshow reviews drug information for MYRBETRIQ™ (mirabegron).Table of ContentsSlide 3: Indication, Dosage & AdministrationSlide 6: Use in Specific PopulationsSlide 8: Clinical PharmacologySlide 11: Warnings & PrecautionsSlide 14: Clinical Safety & EfficacySlide 20: Drug Storage & Supply
OAB treatment is associated with a decreased risk of falls, study finds.
NEW ORLEANS—Overactive bladder (OAB) is associated with an increased risk of falls in elderly patients, researchers reported at the 2015 American Urological Association annual meeting.
Ravishankar Jayadevappa, PhD, and colleagues at the Perelman School of Medicine, University of Pennsylvania in Philadelphia identified 32,587 Medicare fee-for-service patients (mean age 77.7 years) diagnosed with OAB. These patients had a significantly higher prevalence of falls than Medicare patients without OAB (10.2% vs. 5.3%), which translated into 40% increased risk of falls in the OAB group. The OAB patients also had a higher comorbidity burden than non-OAB patients.
Additionally, of the patients with OAB, only 10% received treatment for it. OAB treatment was associated with a significant 8% decreased risk of falls compared with OAB patients who did not receive treatment.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.